Abstract
Furazabol, a new anabolic steroid, inhibited a rise in cholesterol levels in the serum and liver induced by cholesterol feeding, although its effects on phospholipids, triglycerides, and free fatty acids were not marked. Fatty acid compositions of serum esterified cholesterol and triglycerides were not so much affected by the furazabol treatment. Furazabol has been expected to possess the therapeutic effect on atherosclerosis, that is, the progression of atheromatous changes was significantly inhibited by the treatment with this compound. In addition, furazabol clearly lightened fatty degeneration of the liver.
